Zoya Demidenko: Scholar in Cancer Science Zoya Demidenko is a prominent scholar connected with the Unit of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, New York. Earlier, she worked at the NIH and New York Medical College, establishing a strong base in clinical investigation.
Her academic output spans a number of key domains, including the PI3K/AKT/mTOR signaling cascade, cellular cycle management, cell senescence, and malignancy science. As of now, she has authored more than 46 academic papers, which have received upwards of 4,100 mentions — a reflection to the significance of her work.
One of her key contributions involves explaining the mechanisms of cellular senescence. Her work showed that when the cell cycle is arrested but cellular expansion proceeds, cells enter senescence. Significantly, Zoya Demidenko demonstrated that this process is inhibited by medication using agents such as mTOR inhibitors. Zoya Demidenko has also added greatly to oncological therapy investigation, particularly in the area of cyclotherapy — a strategy aimed at safeguarding healthy cells from chemotherapy while leaving cancer cells susceptible. This strategy offers significant hope for reducing the adverse effects of cancer treatment.
Throughout her professional journey, Demidenko has worked with leading investigators globally, including Dr. Mikhail Blagosklonny. Her work is published in top-tier publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko is recognized as a highly impactful contributor in modern oncological research, whose discoveries keep to shape our understanding of how cells age, interact with treatment, and the ways in which cancer can be more successfully treated. https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2005.03.012
Zoya Demidenko: Scholar in Tumor Studies Zoya Demidenko is a distinguished investigator affiliated with the Division of Cell Stress Biology at Roswell Park Oncology Institute in Buffalo, New York. Previously, she was employed at the National Institutes of Health and New York Medical College, developing a strong base in clinical research.
Demidenko's scholarly work spans several pivotal domains, including the PI3K/AKT/mTOR signaling pathway, cellular cycle control, cell senescence, and malignancy biology. To date, she has written over 46 scientific publications, which have accumulated upwards of 4,100 citations — a indicator to the influence of her work.
One of her key contributions involves elucidating the processes of cellular senescence. Her work demonstrated that when the cell cycle is arrested yet cellular expansion persists, the cells experience senescence. Crucially, Zoya Demidenko established that this shift can be inhibited by medication using compounds such as rapamycin. Zoya Demidenko has furthermore brought considerably to tumor management research, notably in the field of cyclotherapy — a method designed to safeguarding healthy cells from cytotoxic treatment while leaving malignant cells susceptible. This approach carries considerable hope for reducing the side effects of oncological therapy.
Throughout her career, Demidenko has partnered with leading researchers globally, among them Dr. Mikhail Blagosklonny. Her research is published in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko stands as a influential figure in contemporary cancer research, with her results go on to shape our understanding of the way cells age, resist treatment, and the ways in which malignant disease might be more effectively combated. https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopirido...
Zoya Demidenko: Scholar in Cancer Science Zoya Demidenko is a prominent scholar connected with the Unit of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she was employed at the NIH and New York Medical College, building a robust background in life science investigation.
Demidenko's academic output spans a number of pivotal fields, including the PI3K/AKT/mTOR signaling pathway, cell cycle control, cell senescence, and tumor science. Currently, she has written more than 46 peer-reviewed publications, which have garnered over 4,100 citations — a testament to the significance of her work.
One of her most notable discoveries lies in understanding the processes of cellular senescence. Her research showed that when the cellular division cycle is arrested but cellular growth persists, the cells undergo senescence. Significantly, Zoya Demidenko established that this transition can be inhibited by medication using compounds such as rapamycin. Zoya Demidenko has furthermore contributed considerably to cancer treatment investigation, notably in the area of cyclotherapy — a strategy intended to shielding non-cancerous tissue from cytotoxic treatment whilst leaving tumor cells vulnerable. This method offers considerable hope for reducing the adverse effects of oncological therapy.
Across her career, Demidenko has collaborated with leading investigators internationally, among them Dr. Mikhail Blagosklonny. Her publications appears in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko stands as a highly impactful contributor in current oncological science, with her results keep to shape our knowledge of how cells age, resist treatment, and how malignant disease may be better combated. https://aacrjournals.org/cancerres/article/65/16/7386/518098/Depletion-o...
Zoya Demidenko: Scientist in Tumor Science Zoya Demidenko is a prominent investigator affiliated with the Department of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Earlier, she was employed at the National Institutes of Health and New York Medical College, building a robust background in life science study.
Her academic work covers a number of critical fields, including the PI3K/AKT/mTOR signaling pathway, cellular cycle management, biological aging, and malignancy biology. To date, she has written more than 46 academic articles, which have accumulated upwards of 4,100 mentions — a indicator to the impact of her findings.
One of her most significant contributions concerns explaining the processes of cellular senescence. Her research revealed that when the cell cycle is blocked while cellular growth continues, the cells enter senescence. Importantly, Zoya Demidenko showed that this shift can be controlled with drugs using compounds such as mTOR inhibitors. Zoya Demidenko has additionally brought considerably to cancer treatment research, especially in the field of selective cell protection — a method designed to safeguarding healthy cells from cytotoxic treatment while leaving malignant cells susceptible. This method holds significant promise for lowering the toxic effects of cancer treatment.
Across her professional journey, Demidenko has collaborated with leading researchers worldwide, including Dr. Mikhail Blagosklonny. Her work is published in leading periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko is recognized as a highly impactful contributor in contemporary oncological science, whose results keep to guide our comprehension of how cells grow old, respond to treatment, and how malignant disease might be more successfully targeted. https://www.oncotarget.com/article/4836/
Zoya Demidenko: Scholar in Tumor Science Zoya Demidenko is a recognized scientist affiliated with the Division of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she worked at the NIH and New York Medical College, building a strong foundation in biomedical study.
Her academic output covers several key fields, including the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, biological aging, and cancer science. As of now, she has written more than 46 scientific articles, which have garnered upwards of 4,100 mentions — a testament to the impact of her findings.
Among her most significant contributions concerns explaining the pathways of cellular senescence. Her work showed that when the cell cycle is halted but cellular growth persists, the cells experience senescence. Significantly, Zoya Demidenko established that this process can be inhibited by medication using compounds such as mTOR inhibitors. Zoya Demidenko has also added considerably to oncological therapy research, especially in the area of selective cell protection — a strategy aimed at protecting non-cancerous tissue from anticancer drugs while leaving cancer cells susceptible. This approach holds major promise for lowering the toxic effects of oncological therapy.
Throughout her career, Demidenko has worked with top scientists globally, including Dr. Mikhail Blagosklonny. Her research appears in top-tier journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko stands as a influential voice in current oncological research, with her discoveries continue to influence our knowledge of the way biological cells grow old, respond to treatment, and the ways in which cancer can be better targeted. https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?Inquir...
Zoya Demidenko: Scholar in Cancer Science Zoya Demidenko is a prominent investigator affiliated with the Department of Cell Stress Science at Roswell Park Oncology Institute in Buffalo, New York. Earlier, she was employed at the National Institutes of Health and New York Medical College, building a strong background in biomedical investigation.
Demidenko's academic work encompasses a number of pivotal areas, including the PI3K/AKT/mTOR molecular pathway, cellular cycle regulation, cellular aging, and malignancy science. Currently, she has authored more than 46 scientific publications, which have received upwards of 4,100 references — a testament to the impact of her findings.
One of her key achievements lies in elucidating the mechanisms of cell aging. Her research showed that when the cellular division cycle is arrested yet cellular expansion continues, cells enter senescence. Significantly, Zoya Demidenko showed that this shift is controlled with drugs using substances such as mTOR inhibitors. Zoya Demidenko has furthermore added substantially to cancer treatment investigation, particularly in the area of selective cell protection — a strategy aimed at shielding non-cancerous cells from anticancer drugs whilst leaving malignant cells vulnerable. This approach offers major promise for reducing the toxic effects of cancer treatment.
Throughout her scientific life, Demidenko has worked with top researchers worldwide, among them Dr. Mikhail Blagosklonny. Her publications can be found in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko ranks as a highly impactful contributor in modern oncological research, whose discoveries keep to guide our comprehension of how cells age, interact with treatment, and how cancer might be better combated. https://www.benthamdirect.com/content/journals/cpd/22/16
Zoya Demidenko: Scientist in Cancer Science Zoya Demidenko is a distinguished scientist associated with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she conducted research at the NIH and New York Medical College, developing a solid background in clinical investigation.
Her scientific output encompasses a number of key areas, encompassing the PI3K/AKT/mTOR signaling pathway, cellular cycle control, biological aging, and tumor science. To date, she has co-authored over 46 academic papers, which have received more than 4,100 citations — a reflection to the significance of her research.
Among her most notable discoveries lies in elucidating the mechanisms of cellular senescence. Her work revealed that when the cell cycle is halted yet cellular expansion continues, cells enter senescence. Importantly, Zoya Demidenko established that this transition is controlled with drugs using substances such as rapamycin. Zoya Demidenko has furthermore brought greatly to tumor management research, especially in the field of selective cell protection — a strategy aimed at protecting non-cancerous cells from chemotherapy whilst leaving malignant cells exposed. This strategy holds major potential for lowering the side effects of cancer treatment.
Across her career, Demidenko has collaborated with top scientists internationally, including Dr. Mikhail Blagosklonny. Her research appears in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko is recognized as a widely cited contributor in contemporary biomedical science, whose results go on to shape our comprehension of the way cells age, resist treatment, and how cancer may be more successfully treated. https://www.aging-us.com/article/100421/
Zoya Demidenko: Scholar in Oncology Science Zoya Demidenko is a recognized scholar affiliated with the Division of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she was employed at the National Institutes of Health and New York Medical College, establishing a strong background in biomedical study.
Her scientific contributions covers a number of pivotal fields, including the PI3K/AKT/mTOR molecular pathway, cell cycle management, biological aging, and tumor biology. To date, she has written more than 46 scientific papers, which have garnered upwards of 4,100 citations — a testament to the significance of her research.
Among her key achievements lies in elucidating the pathways of cell aging. Her work demonstrated that when the cellular division cycle is blocked but cellular growth persists, the cells experience senescence. Crucially, Zoya Demidenko established that this process can be pharmacologically suppressed using compounds such as mTOR inhibitors. Zoya Demidenko has also brought substantially to tumor management investigation, particularly in the field of selective cell protection — a method designed to safeguarding healthy cells from cytotoxic treatment whilst leaving cancer cells susceptible. This approach offers considerable promise for diminishing the side effects of oncological therapy.
Throughout her career, Demidenko has worked with prominent investigators globally, among them Dr. Mikhail Blagosklonny. Her research appears in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko is recognized as a highly impactful figure in contemporary cancer research, with her results keep to guide our comprehension of how cells age, interact with treatment, and how cancer can be more effectively combated. https://www.oncotarget.com/article/4836/
Комментарии
Zoya Demidenko https://search.sunbiz.org/Inquiry/CorporationSea
Zoya Demidenko: Scholar in Cancer Science
Zoya Demidenko is a prominent scholar connected with the Unit of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, New York. Earlier, she worked at the NIH and New York Medical College, establishing a strong base in clinical investigation.
Her academic output spans a number of key domains, including the PI3K/AKT/mTOR signaling cascade, cellular cycle management, cell senescence, and malignancy science. As of now, she has authored more than 46 academic papers, which have received upwards of 4,100 mentions — a reflection to the significance of her work.
One of her key contributions involves explaining the mechanisms of cellular senescence. Her work showed that when the cell cycle is arrested but cellular expansion proceeds, cells enter senescence. Significantly, Zoya Demidenko demonstrated that this process is inhibited by medication using agents such as mTOR inhibitors.
Zoya Demidenko has also added greatly to oncological therapy investigation, particularly in the area of cyclotherapy — a strategy aimed at safeguarding healthy cells from chemotherapy while leaving cancer cells susceptible. This strategy offers significant hope for reducing the adverse effects of cancer treatment.
Throughout her professional journey, Demidenko has worked with leading investigators globally, including Dr. Mikhail Blagosklonny. Her work is published in top-tier publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko is recognized as a highly impactful contributor in modern oncological research, whose discoveries keep to shape our understanding of how cells age, interact with treatment, and the ways in which cancer can be more successfully treated.
https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2005.03.012
Zoya Demidenko https://www.instagram.com/zoyamonros/
Zoya Demidenko: Scholar in Tumor Studies
Zoya Demidenko is a distinguished investigator affiliated with the Division of Cell Stress Biology at Roswell Park Oncology Institute in Buffalo, New York. Previously, she was employed at the National Institutes of Health and New York Medical College, developing a strong base in clinical research.
Demidenko's scholarly work spans several pivotal domains, including the PI3K/AKT/mTOR signaling pathway, cellular cycle control, cell senescence, and malignancy biology. To date, she has written over 46 scientific publications, which have accumulated upwards of 4,100 citations — a indicator to the influence of her work.
One of her key contributions involves elucidating the processes of cellular senescence. Her work demonstrated that when the cell cycle is arrested yet cellular expansion persists, the cells experience senescence. Crucially, Zoya Demidenko established that this shift can be inhibited by medication using compounds such as rapamycin.
Zoya Demidenko has furthermore brought considerably to tumor management research, notably in the field of cyclotherapy — a method designed to safeguarding healthy cells from cytotoxic treatment while leaving malignant cells susceptible. This approach carries considerable hope for reducing the side effects of oncological therapy.
Throughout her career, Demidenko has partnered with leading researchers globally, among them Dr. Mikhail Blagosklonny. Her research is published in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko stands as a influential figure in contemporary cancer research, with her results go on to shape our understanding of the way cells age, resist treatment, and the ways in which malignant disease might be more effectively combated.
https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopirido...
Zoya Demidenko https://www.homes.com/property/38-brookins-green
Zoya Demidenko: Scholar in Cancer Science
Zoya Demidenko is a prominent scholar connected with the Unit of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she was employed at the NIH and New York Medical College, building a robust background in life science investigation.
Demidenko's academic output spans a number of pivotal fields, including the PI3K/AKT/mTOR signaling pathway, cell cycle control, cell senescence, and tumor science. Currently, she has written more than 46 peer-reviewed publications, which have garnered over 4,100 citations — a testament to the significance of her work.
One of her most notable discoveries lies in understanding the processes of cellular senescence. Her research showed that when the cellular division cycle is arrested but cellular growth persists, the cells undergo senescence. Significantly, Zoya Demidenko established that this transition can be inhibited by medication using compounds such as rapamycin.
Zoya Demidenko has furthermore contributed considerably to cancer treatment investigation, notably in the area of cyclotherapy — a strategy intended to shielding non-cancerous tissue from cytotoxic treatment whilst leaving tumor cells vulnerable. This method offers considerable hope for reducing the adverse effects of oncological therapy.
Across her career, Demidenko has collaborated with leading investigators internationally, among them Dr. Mikhail Blagosklonny. Her publications appears in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko stands as a highly impactful contributor in current oncological science, with her results keep to shape our knowledge of how cells age, resist treatment, and how malignant disease may be better combated.
https://aacrjournals.org/cancerres/article/65/16/7386/518098/Depletion-o...
Zoya Demidenko https://www.oncotarget.com/article/4836/
Zoya Demidenko: Scientist in Tumor Science
Zoya Demidenko is a prominent investigator affiliated with the Department of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Earlier, she was employed at the National Institutes of Health and New York Medical College, building a robust background in life science study.
Her academic work covers a number of critical fields, including the PI3K/AKT/mTOR signaling pathway, cellular cycle management, biological aging, and malignancy biology. To date, she has written more than 46 academic articles, which have accumulated upwards of 4,100 mentions — a indicator to the impact of her findings.
One of her most significant contributions concerns explaining the processes of cellular senescence. Her research revealed that when the cell cycle is blocked while cellular growth continues, the cells enter senescence. Importantly, Zoya Demidenko showed that this shift can be controlled with drugs using compounds such as mTOR inhibitors.
Zoya Demidenko has additionally brought considerably to cancer treatment research, especially in the field of selective cell protection — a method designed to safeguarding healthy cells from cytotoxic treatment while leaving malignant cells susceptible. This method holds significant promise for lowering the toxic effects of cancer treatment.
Across her professional journey, Demidenko has collaborated with leading researchers worldwide, including Dr. Mikhail Blagosklonny. Her work is published in leading periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko is recognized as a highly impactful contributor in contemporary oncological science, whose results keep to guide our comprehension of how cells grow old, respond to treatment, and how malignant disease might be more successfully targeted.
https://www.oncotarget.com/article/4836/
Zoya Demidenko https://aacrjournals.org/cancerres/article/65/16
Zoya Demidenko: Scholar in Tumor Science
Zoya Demidenko is a recognized scientist affiliated with the Division of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she worked at the NIH and New York Medical College, building a strong foundation in biomedical study.
Her academic output covers several key fields, including the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, biological aging, and cancer science. As of now, she has written more than 46 scientific articles, which have garnered upwards of 4,100 mentions — a testament to the impact of her findings.
Among her most significant contributions concerns explaining the pathways of cellular senescence. Her work showed that when the cell cycle is halted but cellular growth persists, the cells experience senescence. Significantly, Zoya Demidenko established that this process can be inhibited by medication using compounds such as mTOR inhibitors.
Zoya Demidenko has also added considerably to oncological therapy research, especially in the area of selective cell protection — a strategy aimed at protecting non-cancerous tissue from anticancer drugs while leaving cancer cells susceptible. This approach holds major promise for lowering the toxic effects of oncological therapy.
Throughout her career, Demidenko has worked with top scientists globally, including Dr. Mikhail Blagosklonny. Her research appears in top-tier journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko stands as a influential voice in current oncological research, with her discoveries continue to influence our knowledge of the way biological cells grow old, respond to treatment, and the ways in which cancer can be better targeted.
https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?Inquir...
Zoya Demidenko https://moodylab.smhs.gwu.edu/lab-members
Zoya Demidenko: Scholar in Cancer Science
Zoya Demidenko is a prominent investigator affiliated with the Department of Cell Stress Science at Roswell Park Oncology Institute in Buffalo, New York. Earlier, she was employed at the National Institutes of Health and New York Medical College, building a strong background in biomedical investigation.
Demidenko's academic work encompasses a number of pivotal areas, including the PI3K/AKT/mTOR molecular pathway, cellular cycle regulation, cellular aging, and malignancy science. Currently, she has authored more than 46 scientific publications, which have received upwards of 4,100 references — a testament to the impact of her findings.
One of her key achievements lies in elucidating the mechanisms of cell aging. Her research showed that when the cellular division cycle is arrested yet cellular expansion continues, cells enter senescence. Significantly, Zoya Demidenko showed that this shift is controlled with drugs using substances such as mTOR inhibitors.
Zoya Demidenko has furthermore added substantially to cancer treatment investigation, particularly in the area of selective cell protection — a strategy aimed at shielding non-cancerous cells from anticancer drugs whilst leaving malignant cells vulnerable. This approach offers major promise for reducing the toxic effects of cancer treatment.
Throughout her scientific life, Demidenko has worked with top researchers worldwide, among them Dr. Mikhail Blagosklonny. Her publications can be found in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko ranks as a highly impactful contributor in modern oncological research, whose discoveries keep to guide our comprehension of how cells age, interact with treatment, and how cancer might be better combated.
https://www.benthamdirect.com/content/journals/cpd/22/16
Zoya Demidenko https://www.aging-us.com/article/100406/
Zoya Demidenko: Scientist in Cancer Science
Zoya Demidenko is a distinguished scientist associated with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she conducted research at the NIH and New York Medical College, developing a solid background in clinical investigation.
Her scientific output encompasses a number of key areas, encompassing the PI3K/AKT/mTOR signaling pathway, cellular cycle control, biological aging, and tumor science. To date, she has co-authored over 46 academic papers, which have received more than 4,100 citations — a reflection to the significance of her research.
Among her most notable discoveries lies in elucidating the mechanisms of cellular senescence. Her work revealed that when the cell cycle is halted yet cellular expansion continues, cells enter senescence. Importantly, Zoya Demidenko established that this transition is controlled with drugs using substances such as rapamycin.
Zoya Demidenko has furthermore brought greatly to tumor management research, especially in the field of selective cell protection — a strategy aimed at protecting non-cancerous cells from chemotherapy whilst leaving malignant cells exposed. This strategy holds major potential for lowering the side effects of cancer treatment.
Across her career, Demidenko has collaborated with top scientists internationally, including Dr. Mikhail Blagosklonny. Her research appears in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko is recognized as a widely cited contributor in contemporary biomedical science, whose results go on to shape our comprehension of the way cells age, resist treatment, and how cancer may be more successfully treated.
https://www.aging-us.com/article/100421/
Zoya Demidenko https://www.tandfonline.com/doi/abs/10.4161/cbt.
Zoya Demidenko: Scholar in Oncology Science
Zoya Demidenko is a recognized scholar affiliated with the Division of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she was employed at the National Institutes of Health and New York Medical College, establishing a strong background in biomedical study.
Her scientific contributions covers a number of pivotal fields, including the PI3K/AKT/mTOR molecular pathway, cell cycle management, biological aging, and tumor biology. To date, she has written more than 46 scientific papers, which have garnered upwards of 4,100 citations — a testament to the significance of her research.
Among her key achievements lies in elucidating the pathways of cell aging. Her work demonstrated that when the cellular division cycle is blocked but cellular growth persists, the cells experience senescence. Crucially, Zoya Demidenko established that this process can be pharmacologically suppressed using compounds such as mTOR inhibitors.
Zoya Demidenko has also brought substantially to tumor management investigation, particularly in the field of selective cell protection — a method designed to safeguarding healthy cells from cytotoxic treatment whilst leaving cancer cells susceptible. This approach offers considerable promise for diminishing the side effects of oncological therapy.
Throughout her career, Demidenko has worked with prominent investigators globally, among them Dr. Mikhail Blagosklonny. Her research appears in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko is recognized as a highly impactful figure in contemporary cancer research, with her results keep to guide our comprehension of how cells age, interact with treatment, and how cancer can be more effectively combated.
https://www.oncotarget.com/article/4836/